SLC1A5 and cancer: Furthermore, pharmacological blockade of ASCT2 with V-9302 preferentially inhibits glutamine use in cancer cells, which upregulates the immune checkpoint factor PD-L1 by impairing the activity of Sarco/ER Ca2+-ATPase (SERCA).